Industry Reports & Benchmarks

Dozens of reports claim to capture AI’s progress in healthcare each year, and the headline figures they produce vary by wide margins. The same phenomenon, physician AI use, appears at dramatically different rates depending on who was surveyed, what question was asked, and who funded the research. This chapter is a navigation guide to the major report types, their methodologies, and their limitations. For current statistics, the sources listed here are the appropriate destination. The framework for reading them critically does not change as rapidly as the numbers do.

Learning Objectives

After reading this chapter, you will be able to:

  • Locate the major annual reports on AI in healthcare and access them directly
  • Distinguish funding reports from adoption surveys from consulting analyses from government data
  • Apply a four-question critical framework to any industry report
  • Recognize the specific ways industry figures are commonly misinterpreted
  • Identify which benchmarks matter for clinical AI evaluation and why

The core problem: Industry reports on AI in healthcare generate widely varying figures because they measure different things. “Adoption” can mean intent to adopt, a purchased license, a deployed system, or active daily clinical use. Knowing which was measured changes the interpretation completely.

Five report types, five different answers to the same question:

Type Examples What It Actually Measures
Market/Funding Rock Health, CB Insights Investment dollars and deal count
Adoption Surveys AMA, HIMSS Self-reported clinician or executive behavior
Consulting McKinsey, Deloitte Executive intention and organizational strategy
Vendor Performance KLAS IT purchaser satisfaction with vendors
Government/Independent ONC, RAND, Stanford AI Index Infrastructure, policy, and cross-sector AI trends
Governance/Safety CHAI, ECRI Transparency standards and safety hazards

The four questions to ask any report: 1. Who funded it? 2. What exactly was measured? 3. Who was in the sample and how were they recruited? 4. What conflicts of interest apply?

Benchmarks: what the numbers mean

  • Funding volume measures investor activity, not clinical utility
  • Self-reported adoption conflates occasional use with routine clinical integration
  • Accuracy on benchmark datasets does not predict real-world performance
  • External prospective validation is the evidence standard that matters clinically

For current figures: Go directly to the sources listed in this chapter. Industry statistics change faster than handbook revision cycles.

Introduction

The volume of market commentary on healthcare AI is disproportionate to the clinical evidence base. A single week can produce a funding digest, a consulting firm’s transformation analysis, a specialty society survey, and a government policy brief, each presenting different figures for the same underlying question.

This is not a failure of research quality across the field. It is a consequence of what each report type is designed to answer. Funding trackers count investment dollars. Adoption surveys count self-reported behavior. Consulting reports capture executive intentions. Government reports track infrastructure. Each instrument answers a different question, and the figures from each reflect that scope.

The problem arises when headline numbers migrate between contexts. An executive survey showing high intent to adopt AI becomes a claim about clinical deployment. A funding total for all digital health becomes a claim about AI in clinical practice. Physicians and institutional leaders benefit from understanding each source’s methodology before drawing conclusions about AI’s actual clinical role.

This chapter is updated as significant new report sources emerge, but the framework for reading these reports is more durable than any single year’s statistics.

Report Types

Understanding what category a report belongs to is the first interpretive step.

Market and Funding Reports

These reports track investment activity: how much capital moved into digital health or healthcare AI, which segments attracted it, and how deal structures evolved. They are published by venture intelligence firms and nonprofit research organizations, and they draw on disclosed funding rounds and deal data.

What they show: which parts of healthcare AI are attracting capital, at what stage, and from which investors.

What they do not show: clinical outcomes, patient benefit, FDA authorization rates, or whether deployed products work.

Primary sources:

  • Rock Health publishes the most widely cited annual U.S. digital health funding overview, released each January for the prior year. Free access.
  • CB Insights State of Digital Health publishes global digital health market research covering deal count, funding concentration, and AI’s share of investment. Registration required for full access.
  • Silicon Valley Bank Healthcare Investments and Exits covers healthcare investment and exits, with dedicated AI subsections in recent editions. Free access.

Reading note: High funding concentration toward AI is a leading indicator of product availability, not clinical validation. The years with the highest digital health investment preceded periods in which many funded products failed to achieve clinical adoption or demonstrate patient benefit.

Clinical Adoption Surveys

These surveys ask clinicians or health system leaders what AI tools they use or intend to use. They generate the “X% of physicians use AI” headlines.

Methodological variables that explain why survey results differ so widely:

  • Definition of use: Does “use AI” include an ambient documentation tool, a search interface, a risk scoring model, or only clinical decision support? Surveys vary widely, and the definition is often not in the headline.
  • Sampling frame: AMA member panels, HIMSS conference attendees, and random probability samples produce different results from the same profession.
  • Stage of adoption: Questions about “use,” “plan to use,” “organization has deployed,” and “I use daily in patient care” target different behaviors.

Primary sources:

Reading note: Recent AMA survey waves include use cases such as summarizing medical research, creating patient-facing materials, and documentation support. An adoption figure that combines these categories describes a substantially different phenomenon than diagnostic decision support adoption.

Consulting and Research Analyses

Consulting firms produce healthcare AI analyses to support advisory relationships with health systems, insurers, and technology vendors. The methodological quality varies. Most operate under a conflict of interest: firms that advise clients on AI adoption have revenue interests in characterizing the AI opportunity favorably.

Primary sources:

  • McKinsey Healthcare AI Research surveys health system, payer, and health services technology executives. Published periodically, free with registration. Economic impact estimates for administrative AI appear in separate research papers cited in the Policy chapter of this handbook.
  • Deloitte Global Health Care Outlook surveys health system executives annually across multiple countries. Free access; published late each year for the following year.
  • Accenture Technology Vision is a cross-industry annual report covering technology trends, with healthcare as one vertical. Free access; the report is typically linked from the announcement page.

Reading note: These reports survey executives, not clinicians, and capture intention and expectation at the organizational level. “Our organization is exploring generative AI” includes organizations that have attended a vendor briefing. “Adopted” in executive surveys does not mean deployed at the point of care.

Vendor Performance Research: KLAS

KLAS Research surveys IT decision-makers at provider organizations about vendor performance and product adoption. Unlike consulting reports, KLAS data comes from purchasers rating products they have bought and implemented.

The Healthcare AI series (klasresearch.com) tracks which AI use cases are most widely purchased and which vendors lead in buyer satisfaction. Reports are paywalled; access requires a KLAS account or institutional subscription.

KLAS data is useful for procurement decisions and understanding which vendors have traction with health system IT departments. It does not assess clinical outcomes. A high KLAS rating reflects purchaser satisfaction with the vendor relationship and implementation experience, not patient-level performance.

Government and Independent Research

Government agencies and research nonprofits publish on longer timelines but with greater methodological rigor and without vendor conflicts of interest. These are the most defensible sources for policy and institutional decisions.

Primary sources:

  • ONC Reports to Congress track U.S. health IT infrastructure: EHR adoption, health information exchange, and interoperability progress. Published annually, freely accessible. The reports cover the data substrate on which clinical AI depends, not AI performance directly.
  • RAND Corporation Healthcare Research covers governance, equity, and workforce implications of AI in healthcare, typically funded by government agencies or foundations without vendor sponsorship. All reports are open access.
  • Federal Health IT Strategic Plan 2024-2030 sets ONC’s priorities for the decade. Freely accessible; relevant as context for regulatory and infrastructure direction.
  • Stanford AI Index tracks cross-sector AI trends and includes a dedicated medicine chapter in recent editions. Free access; useful for benchmark saturation, FDA authorization trends, research output, and model capability context.

Reading note: Government reports focus on infrastructure and policy rather than clinical AI performance benchmarks. They are authoritative for interoperability and EHR adoption claims. For clinical performance evidence, peer-reviewed literature and specialty chapter content in this handbook are the appropriate sources.

Governance and Safety Resources

These sources are not market reports, but they help physicians interpret whether a health AI product has moved beyond marketing claims into basic transparency, safety, and governance practice.

Primary sources:

  • Coalition for Health AI Applied Model Card provides a structured template for documenting a health AI solution’s intended use, performance, fairness, safety, transparency, security, privacy, and workflow context. Free access; useful for procurement and local governance review.
  • ECRI AI Resources summarize patient-safety concerns related to AI-enabled health technologies. Free access; useful as a counterweight to market and adoption reports.

Reading note: Model cards and safety hazard lists are decision-support documents, not proof of clinical effectiveness. They help define what must be checked before deployment; they do not replace prospective validation.

Critical Reading Framework

Four questions applied consistently reveal how much weight any industry report deserves. This framework does not change as the reports themselves update.

Who funded it?

The source of funding shapes what questions get asked, how favorably the findings are framed, and which results receive emphasis. Vendor-sponsored surveys about vendor satisfaction and consulting firms that advise health systems on AI adoption share similar incentive structures. Government agencies and research nonprofits have weaker commercial incentives, though institutional interests still exist.

No report is entirely free of perspective. The question is whether the conflict of interest is disclosed and whether the methodology is transparent enough to evaluate independently.

What exactly was measured?

The spectrum from organizational intent to clinical impact runs:

awareness -> interest -> exploration -> pilot -> procurement -> deployment -> active use -> clinical integration -> measured patient outcome

Most industry reports sit at exploration, procurement, or deployment. Few reach measured patient outcome. Headlines routinely collapse this spectrum. “Adopted AI” at the executive survey level and “AI integrated into routine clinical care with demonstrated outcomes” are not the same claim. Confirming which stage was measured requires reading the methods section, not the executive summary.

How was the sample selected?

Convenience samples of willing respondents, email panels, and conference attendees systematically overrepresent early adopters. Health system executives at a digital health conference are not representative of community hospitals. AMA member panels overrepresent physicians engaged enough to participate in professional society surveys.

Sample size matters less than representativeness. A large convenience sample may be less informative than a smaller probability sample.

What is the denominator?

A percentage is only interpretable relative to what it is a percentage of. “42% of digital health funding went to AI” is a share of dollars, not a share of clinical deployments, patients served, or outcomes demonstrated. Funding concentration and clinical impact are independent variables. Confirming the denominator requires reading past the headline.

Benchmarks: What the Numbers Mean

Industry reports cite several types of benchmarks when describing AI performance. Each measures something different and supports different conclusions.

Market Benchmarks

Funding volume measures investor activity. It is a leading indicator of product availability, not clinical utility. Years of high investment in digital health have preceded periods in which many funded products failed to reach clinical adoption.

Deal count measures the number of distinct funding transactions. Declining deal count with rising total funding indicates fewer but larger bets on established companies. This signals market consolidation, not necessarily clinical maturation.

Adoption Benchmarks

Self-reported use captures behavior as survey respondents understand and report it. The same clinician may answer “yes” to using AI whether they mean ambient documentation software, an AI-assisted search tool, or a clinical decision support model. These are not equivalent from a patient-care standpoint.

License acquisition at the health system level captures what IT departments have purchased. Products purchased and deployed to desktop but rarely used by clinicians appear as “adopted” in procurement-based surveys.

The gap between “adopted” in executive surveys and “used daily in patient care” in clinician surveys is consistently large and rarely reported in industry headlines.

Clinical Performance Benchmarks

Accuracy on benchmark datasets (standardized test sets such as USMLE-style question banks or image classification challenges) measures a model’s performance under idealized conditions. Benchmark performance establishes a capability floor; it does not predict real-world performance with different patient populations, imaging equipment, or documentation practices.

AUC-ROC, sensitivity, and specificity from development-phase validation measure performance on held-out data from the same institution or dataset. External validation on independent datasets from different healthcare settings is a substantially higher bar.

Prospective clinical utility measures what happens to patient outcomes when a tool is deployed in routine care. This is the standard that matters for clinical decisions and the rarest type of evidence in the current healthcare AI literature.

For a full explanation of these metrics and how to evaluate them, see AI Fundamentals for Clinicians.

Staying Current

New healthcare AI reports appear continuously. The sources below publish on predictable annual or quarterly cycles; checking them directly for current figures is more reliable than relying on any static summary.

The organizational landscape changes slowly: Rock Health, AMA, HIMSS, McKinsey, Deloitte, KLAS, ONC, RAND, Stanford HAI, CHAI, ECRI, and AHA have published in this space and are likely to continue. Specific reports get updated; the organizations producing them do not change as rapidly.

Where to check for new reports:

For clinical performance evidence on specific AI tools, FDA authorization status, and validated specialty applications, see the specialty chapters of this handbook. Industry reports describe the environment in which clinical AI is developed, funded, and sold. They are a useful compass, not a clinical reference.